Literature DB >> 24969551

Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor.

Daniel Antonio de Luis1, Rocío Aller, Olatz Izaola, R Bachiller, D Pacheco.   

Abstract

BACKGROUND: The role of GLP-1 R variants on body weight response after dietary intervention is unclear.
OBJECTIVE: Our aim was to evaluate the effect of this polymorphism on cardiovascular risk factors, adipokine levels and weight loss secondary to a high monounsaturated fat vs. a high polyunsaturated fat hypocaloric diets in obese subjects.
DESIGN: 391 obese subjects were randomly allocated to one of these two diets for a period of 3 months; diet M (high monounsaturated fat hypocaloric diet) and diet P (high polyunsaturated (PUFAs) fat hypocaloric diet).
RESULTS: Two hundred and twelve patients (54.2 %) had the genotype GG (wild group) and 179 (45.8 %) patients had the next genotypes; GA (146 patients, 37.3 %) or AA (33 patients, 8.7 %) (Mutant group). With both diets and in wild-type and mutant-type groups, BMI, weight, fat mass, waist circumference and systolic blood pressure decreased. Anthropometric parameters were higher in non-A-allele carriers than A-allele carriers. With both diets and in both genotypes, leptin, insulin levels and HOMA decreased. With the diet P and in wild genotype, total cholesterol and LDL-cholesterol levels decreased, too.
CONCLUSION: Our data showed a lack of association of rs6923761 GLP-1 R polymorphism with weight loss after a high monounsaturated fat and a high polyunsaturated fat hypocaloric diets. Better anthropometric parameters in obese subjects with the mutant allele (A) of rs6923761 GLP-1 R polymorphism were observed. Insulin levels and HOMA decreased in non-A carriers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24969551     DOI: 10.1007/s40618-014-0116-3

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

Review 1.  The glucagon-like peptides.

Authors:  T J Kieffer; J F Habener
Journal:  Endocr Rev       Date:  1999-12       Impact factor: 19.871

2.  Evaluation of an enzyme immunometric assay to measure serum adiponectin concentrations.

Authors:  Pauli Suominen
Journal:  Clin Chem       Date:  2004-01       Impact factor: 8.327

3.  Validation of a kinetic model for the reactions in RIA.

Authors:  Maria J Duart Duart; Consuelo Olivas Arroyo; José Luis Moreno Frígols
Journal:  Clin Chem Lab Med       Date:  2002-11       Impact factor: 3.694

Review 4.  Adipocytokines: emerging therapeutic targets.

Authors:  Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

5.  Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.

Authors:  L A Scrocchi; B A Marshall; S M Cook; P L Brubaker; D J Drucker
Journal:  Diabetes       Date:  1998-04       Impact factor: 9.461

6.  The hormone resistin links obesity to diabetes.

Authors:  C M Steppan; S T Bailey; S Bhat; E J Brown; R R Banerjee; C M Wright; H R Patel; R S Ahima; M A Lazar
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

7.  Usefulness of high-sensitivity IL-6 measurement for clinical characterization of patients with coronary artery disease.

Authors:  Valter Lubrano; Franca Cocci; Debora Battaglia; Angela Papa; Paolo Marraccini; Gian Carlo Zucchelli
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

8.  Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance.

Authors:  Andreas Pfützner; Matthias Langenfeld; Thomas Kunt; Mirjam Löbig; Thomas Forst
Journal:  Clin Lab       Date:  2003       Impact factor: 1.138

9.  Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study.

Authors:  Airani Sathananthan; Chiara Dalla Man; Francesco Micheletto; Alan R Zinsmeister; Michael Camilleri; Paula D Giesler; Jeanette M Laugen; Gianna Toffolo; Robert A Rizza; Claudio Cobelli; Adrian Vella
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

10.  Pharmacological characterization of human incretin receptor missense variants.

Authors:  Jean-Philippe Fortin; Jonathan C Schroeder; Yuantee Zhu; Martin Beinborn; Alan S Kopin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

View more
  10 in total

Review 1.  Determinants of body fat distribution in humans may provide insight about obesity-related health risks.

Authors:  Aaron P Frank; Roberta de Souza Santos; Biff F Palmer; Deborah J Clegg
Journal:  J Lipid Res       Date:  2018-08-10       Impact factor: 5.922

2.  Effects of a high-protein/low-carbohydrate versus a standard hypocaloric diet on adipocytokine levels and cardiovascular risk factors during 9 months, role of rs6923761 gene variant of glucagon-like peptide 1 receptor.

Authors:  D A de Luis; R Aller; O Izaola; E Romero
Journal:  J Endocrinol Invest       Date:  2015-05-27       Impact factor: 4.256

3.  Prevalence of overweight/obesity, abdominal obesity and metabolic syndrome and atypical cardiometabolic phenotypes in the adult Romanian population: PREDATORR study.

Authors:  S Popa; M Moţa; A Popa; E Moţa; C Serafinceanu; C Guja; D Catrinoiu; N Hâncu; R Lichiardopol; C Bala; A Popa; G Roman; G Radulian; R Timar; B Mihai
Journal:  J Endocrinol Invest       Date:  2016-04-28       Impact factor: 4.256

Review 4.  Dietary Fatty Acid Composition Modulates Obesity and Interacts with Obesity-Related Genes.

Authors:  Shatha S Hammad; Peter J Jones
Journal:  Lipids       Date:  2017-09-09       Impact factor: 1.880

Review 5.  Does dietary fat affect inflammatory markers in overweight and obese individuals?-a review of randomized controlled trials from 2010 to 2016.

Authors:  Vibeke H Telle-Hansen; Jacob J Christensen; Stine M Ulven; Kirsten B Holven
Journal:  Genes Nutr       Date:  2017-10-04       Impact factor: 5.523

Review 6.  Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.

Authors:  Gaia Chiara Mannino; Francesco Andreozzi; Giorgio Sesti
Journal:  Diabetes Metab Res Rev       Date:  2019-01-07       Impact factor: 4.876

Review 7.  Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.

Authors:  Joanna Michałowska; Ewa Miller-Kasprzak; Paweł Bogdański
Journal:  Nutrients       Date:  2021-01-25       Impact factor: 5.717

Review 8.  Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.

Authors:  Jasna Klen; Vita Dolžan
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

9.  Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study.

Authors:  Evangelia Eirini Tsermpini; Katja Goričar; Blanka Kores Plesničar; Anja Plemenitaš Ilješ; Vita Dolžan
Journal:  Front Mol Neurosci       Date:  2022-06-09       Impact factor: 6.261

10.  Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.

Authors:  Mona Mashayekhi; Jessica R Wilson; Scott Jafarian-Kerman; Hui Nian; Chang Yu; Megan M Shuey; James M Luther; Nancy J Brown
Journal:  Diabetes Obes Metab       Date:  2020-10-22       Impact factor: 6.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.